Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Surveillance for hepatobiliary cancers in primary sclerosing cholangitis

Publish date:: October 9, 2019

Key clinical point: Surveillance for hepatobiliary cancers is advised in patients with primary sclerosing cholangitis.

Major finding: Patients with primary sclerosing cholangitis should be checked every 6-12 months for cholangiocarcinoma.

Study details: Clinical update from the American Gastroenterological Association.

Disclosures: Two authors declared consultancies, grants, and research contracts with the pharmaceutical sector. No other conflicts of interest were declared.

Citation:

Bowlus C et al. Clin Gastroenterol Hepatol. 2019 Jul 12. doi: 10.1016/j.cgh.2019.07.011.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,